{"id":"NCT01480258","sponsor":"MCM Vaccines B.V.","briefTitle":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","officialTitle":"A Phase III Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-23","primaryCompletion":"2013-10-09","completion":"2013-10-09","firstPosted":"2011-11-28","resultsPosted":"2019-04-02","lastUpdate":"2019-04-02"},"enrollment":1315,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Bacterial Infections","Virus Diseases"],"interventions":[{"type":"BIOLOGICAL","name":"PR5I","otherNames":["V419","Vaxelis®"]},{"type":"BIOLOGICAL","name":"Rotavirus vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"Prevenar 13™","otherNames":[]},{"type":"BIOLOGICAL","name":"INFANRIX™ hexa","otherNames":[]}],"arms":[{"label":"PR5I","type":"EXPERIMENTAL"},{"label":"INFANRIX™ hexa","type":"ACTIVE_COMPARATOR"}],"summary":"This study will determine whether participants who receive V419 (PR5I) at 2, 4, and 11 to 12 months of age have an acceptable response to the vaccine. This study will also determine whether the immune response to V419 is similar to that of participants who received a licensed vaccine control. The primary hypothesis is that participants who receive PR5I at 2, 4, and 11 to 12 months have an acceptable response rate to all PR5I-contained antigens at one month after the Toddler dose of PR5I.","primaryOutcome":{"measure":"Acceptability of Antibody (Ab) Response or Seroresponse Rates to All Antigens Contained in PR5I Vaccine One Month After the Toddler Dose of PR5I (11 to 12 Months of Age)","timeFrame":"1 month after Toddler dose of PR51 (post-toddler dose)","effectByArm":[{"arm":"PR5I","deltaMin":89.87,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"},{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"46 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":14},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27288217"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":653},"commonTop":["Irritability","Crying","Somnolence","Injection site pain","Pyrexia"]}}